Retrospective Analysis of Clinicoepidemiological Factors in Endometrial Cancer

Abstract

SUMMARY E ndometrial cancer is the most common female genital cancer in the developing world, with adenocarcinoma of the endometrium the most common type (De Haydu et al., 2015). In our study we reviewed of medical records on 104 patients including demographic data and clinic-pathological factors were reported, including age, performance status (ECOG), comorbidities, risk factors, surgery, adjuvant treatment, metastatic treatment, treatment response and survival rates were collected. The exact cause of endometrial cancer is unknown. An increased level of estrogen may play a role. Estrogen helps stimulate the buildup of the lining of the uterus (Boggess et al., 2013). Our population under study had: median age of the studied population was 61 years (range: 45-77), majority of our patients (86.5%) had good ECOG performance status (1), (57.6%) of the patients were presented to us with stage I disease, most common symptoms at presentation was abnormal vaginal bleeding in (96.15%) and the most common pathological subtype was endometrioid adenocarcinoma (88.4%). As regard adjuvant treatment fifty patients (66.7% of total patients received adjuvant treatment) received Rth on whole pelvis till 50 Gy. Radiotherapy improved the OS and DFS. The meta-analysis and Cochrane Review also found a trend to improve survival with the addition of radiation in patients with at least 2 risk factors (age, lymphovascular space involvement) including grade 3 and stage IC disease (Kong et al., 2007). In our study, twenty five patients (33.3%) received adjuvant Cth, twenty three patients received Taxol/Carb with statistically significant improvement in OS. It is safe and efficient to use Taxol/Carb as first line of treatment in patients with advanced endometrial cancer with overall response rates ranging from 40% to 63% (Nomura et al., 2011). Thirteen patients received Taxol/Carb as first line of treatment in metastatic patients with statistically improvement in OS and PFS. The median progression free survival was 15 months and the median overall survival was 25 months in metastatic endometrial cancer patients who received Taxol/Carb for 6-9 cycles (Pectasides et al., 2008).